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Abstract
Background: Primary coenzyme Q10 (CoQ10) deficiencies are clinically and
genetically heterogeneous group of disorders associated with defects of genes
involved in the CoQ10 biosynthesis pathway. COQ7-associated CoQ10 deficiency
is very rare and only two cases have been reported.
Methods and Results: We report a patient with encephalo-myo-nephro-cardiopa-
thy, persistent lactic acidosis, and basal ganglia lesions resulting in early infantile
death. Using whole exome sequencing, we identified compound heterozygous var-
iants in the COQ7 gene consisting of a deletion insertion resulting in frameshift
[c.599_600delinsTAATGCATC, p.(Lys200Ilefs*56)] and a missense substitution
[c.319C>T, p.(Arg107Trp), NM_016138.4]. Skin fibroblast studies showed
decreased combined complex II + III activity and reduction in CoQ10 level.
Conclusion: This third patient presenting with lethal encephalo-myo-nephro-
cardiopathy represents the severe end of this ultra-rare mitochondrial disease
caused by biallelic COQ7 mutations. The response to CoQ10 supplement is poor
and alternative treatment strategies should be developed for a more effective
management of this disorder.
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1 | INTRODUCTION
Coenzyme Q10 (CoQ10), known as ubiquinone, serves as a
mitochondrial respiratory chain electron carrier shuttling elec-
trons from NADH:ubiquinone oxidoreductase (complex I) or
succinate dehydrogenase (complex II) to ubiquinol cytochrome
c reductase (complex III) in the inner mitochondrial mem-
brane.1 Besides, CoQ10 functions as an antioxidant to provide
protection against lipid peroxidation as well as DNA and pro-
tein oxidation in animal cells.1 CoQ10 consists of a polar ben-
zoquinone ring for redox reaction and a hydrophobic isoprenyl
tail for diffusion in lipid bilayer and interaction with redox
enzymes.2 In eukaryotes, at least 16 enzymes have been identi-
fied or proposed for CoQ1010 biosynthesis.
3
Primary CoQ10 deficiency is clinically and genetically het-
erogeneous with an extremely wide spectrum of clinical mani-
festations. A recent review classified the phenotypes according
to the genetic defects of the CoQ10 biosynthesis pathway:
(a) glomerular renal involvement manifested as steroid resis-
tant nephrotic syndrome (SRNS) associated with the defects
of PDSS2 (COQ1 subunit 2), COQ2, COQ6, or COQ8B;
(b) encephalomyopathy with COQ4, COQ7, or COQ9 defects
involving hypertrophic cardiomyopathy, lactic acidosis and
tubulopathy; and (c) predominant cerebellar ataxia involving
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only COQ8A.4 The genes associated with CoQ10 deficiency
were suggested to have additional roles in mitochondrial
homeostasis in addition to CoQ10 biosynthesis, which may
account for the clinical heterogeneity.4 The biological mecha-
nisms regulating various clinical phenotypes associated with
different genetic defects are still unclear.
Primary CoQ10 deficiency caused by defect of the
COQ7 gene is the most rarely reported. COQ7 encodes for
5-demethoxyubiquinone hydroxylase that catalyzes the hydrox-
ylation of 2-polyprenyl-3-methyl-6-methoxy-1,4-benzoquinol
(DMQH2), a critical step in CoQ10 biosynthesis. In addition to
CoQ10 biosynthesis, a previous study identified a nuclear form
of COQ7 which was increased in response to reactive oxygen
species (ROS) and functioned independently to regulate ROS
metabolism, stress responses and longevity.5 The first case
reported was a 9-year-old Syrian boy with mildly progressive
encephalo-neuro-nephro-cardiopathy which was stabilized by
CoQ10 treatment.
6 The second case reported recently was a
6-year-old girl presented with spasticity and bilateral sensori-
neural hearing loss.7 Here, we report a Chinese boy with com-
pound heterozygous COQ7 variants, presenting with a
phenotype of mitochondrial encephalo-myo-nephro-cardiopa-
thy, persistent lactic acidosis, basal ganglia lesions and decrease
in CoQ10 level in the skin fibroblasts. This is the third reported
case of COQ7 defect associated with primary CoQ10 defi-
ciency. The discovery of the present case has led to a wider
clinical phenotypic spectrum of COQ7-associated CoQ10 defi-
ciency ranging from spasticity or mildly progressive encephalo-
neuro-nephro-cardiopathy to a fatal multisystemic disorder.
2 | CASE REPORT
2.1 | Clinical history
The index case was born of a nonconsanguineous Chinese cou-
ple as the second twin of a dichorionic diamniotic twin preg-
nancy. The first twin was healthy and unaffected. Our index
patient was noted to have intrauterine growth restriction, card-
iomegaly and tricuspid regurgitation since antenatal period. He
was born at 33 weeks of gestation by emergency cesarean
section due to oligohydramnios and abnormal Doppler signals.
His birth weight was 1.6 kg (10th percentile) with satisfactory
Apgar scores (Table 1). Surfactant was given shortly after birth.
However, he developed heart failure with respiratory dis-
tress since day 4 of life, culminating in a re-intubation at day
24 of life. Repeated echocardiography at 26 days old
showed severe hypertrophic cardiomyopathy with moder-
ately impaired right systolic function, moderate tricuspid
regurgitation and pericardial effusion. There was significant
bi-atrial enlargement suggestive of diastolic dysfunction,
with mild outflow obstruction at both ventricles. Heart fail-
ure symptoms persisted despite optimal medical therapy.
Respiratory-wise, he was ventilator-dependent for 7 months
due to heart failure, with subsequent extubation to nasal can-
nula. Since 10 months, he was started on noninvasive ventila-
tion due to central hypoventilation.
Neurologically, he was noted to have generalized hypotonia,
ptosis, bilateral severe visual impairment, profound hearing
impairment with progressive loss of muscle bulk and muscle
weakness especially over bilateral lower limbs despite pre-
served jerks. Soft dysmorphic features were also noted with
frontal bossing, low nasal bridge and sparse hair. He also devel-
oped infantile spasms since 10 months of life, which were
responsive to phenobarbitone and vigabatrin. Magnetic reso-
nance imaging (MRI) of the brain at 10 months of age showed
multiple T2W hyperintense cystic changes involving bilateral
corona radiata, basal ganglia and thalami, compatible with old
lacunar infarcts, cerebral atrophy with encephalomalacic
changes in bilateral frontal lobes, features of periventricular
leukomalacia as well as doublet lactate peaks on magnetic reso-
nance spectroscopy (see Figure 1A and B).
Ultrasound of the urinary system showed multiple renal
cysts and a diffuse increase in renal parenchymal echogenicity
with accentuation of cortico-medullary differentiation. Renal
function was unremarkable.
Metabolic workup showed persistently elevated lactate up to
17 mmol/L with a raised lactate/pyruvate ratio of 50. His ala-
nine level was up to 463 μmol/L (reference: 143-439 μmol/L).
Urine for organic acids showed increased lactate, pyruvate,
3-hydroxybutyrate, dicarboxylic aciduria and increased excre-
tions of Kreb cycle intermediates. These, together with the neu-
roimaging findings were highly suggestive of a mitochondrial
disorder. He was started on CoQ10 at 2 months of life and the
dose was further stepped up to 20 mg/kg/day at 12 months of
life. Around the same time, he had progressive cardiorespiratory
deterioration and was eventually succumbed during an episode
of deterioration due to sepsis.
2.2 | Genetic analysis
Whole exome sequencing (WES) and bioinformatics ana-
lyses were performed as described previously.8,9 The vari-
ants called were annotated by Oncotator version 1.8.0.0,
filtered and selected using gene panels associated with
mitochondrial diseases and with strong support of mito-
chondrial localization suggested in MitoCarta 2.0. Com-
pound heterozygous variants were identified in the COQ7
gene. The variants were further confirmed by Sanger
sequencing. One of the variants was a deletion insertion
resulting in frameshift [c.599_600delinsTAATGCATC, p.
(Lys200Ilefs*56), NM_016138.4] in exon 6 which formed
the stop codon 37 amino acid downstream to the wildtype
stop codon. Another variant was a missense one [c.319C>T,
p.(Arg107Trp), NM_016138.4] in exon 3. Both variants were
24 KWONG ET AL.
TABLE 1 Clinical features of the three cases of COQ7 pathogenic variants reported in literature
Freyer et al Wang et al Index patient
Ancestry Syrian – Chinese
Parents Consanguineous Consanguineous Nonconsanguineous
Antenatal Oligohydramnios, fetal lung
hypoplasia, growth retardation
Gestational diabetes Oligohydramnios, growth
retardation, fetal cardiomegaly
Gestational age Full term 37 wk 33 wk
Respiratory Lung hypoplasia with persistent
pulmonary hypertension of
newborn
– Central hypoventilation
Renal Renal dysfunction with small
dysplastic kidneys with impaired
cortical differentiation (resolved
upon follow-up)
– Multiple renal cysts and diffuse
increase in renal parenchymal
echogenicity with accentuation
of cortico-medullary
differentiation
Cardiovascular Left ventricular cardiac
hypertrophy (with subsequent
regression), systemic
hypertension
– Severe hypertrophic
cardiomyopathy with
pericardial effusion, moderate
tricuspid regurgitation
Growth and feeding Postnatal growth retardation with
oromotor dysfunction requiring
gastrostomy
Normal Postnatal growth retardation with
oromotor dysfunction
requiring tube feeding
Neurology and
developmental
outcome
Normal MRI brain Normal MRI brain MRI brain showed subdural
hematoma, basal ganglial and
thalami hypodensities with
abnormal lactate peak
Distal contractures since birth with
progressive peripheral
sensorimotor polyneuropathy,
axonal, and demyelinating type
Generalized muscle wasting, more
prominent in the legs, also
affecting temporalis muscle
Generalized hypotonia with
progressive myopathy
clinically
Mild learning difficulties at 9 y
old, never learned to stand or
walk independently
Normal early developmental
milestones, followed by
language delay since 14 mo,
progressive motor regression
since second year and became
wheelchair bound at 3
Global developmental delay with
developmental age below
3 mo across all domains at 1 y
Hearing Combined sensorineural and
conduction hearing impairment
Bilateral low frequency
sensorineural hearing loss
Bilateral profound hearing
impairment in range of 2-4 Hz
Vision Visual dysfunction – Lack of visual following
Respiratory chain
enzyme activities
Complex I + III and IV deficiency – Complex II + III deficiency with
normal isolated activity of
complex II and complex III
COQ7 variants
identified
p.(Val141Glu) p.(Leu111Pro) p.(Lys200Ilefs*56), p.
(Arg107Trp)
Response to
treatment
Dosage of CoQ10 not available CoQ10 11.4 mg/kg twice daily CoQ10 4 mg/kg/day since 2 mo
Regression stalled No obvious improvement Stepped up to 20 mg/kg/day at
1 y
Significant reduction in
neuromuscular pain
No deterioration or worsening
spasticity
No obvious response to
treatment
Abbreviation: MRI, magnetic resonance imaging; y, years; mo, months.
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not found in East Asian population according to The Genome
Aggregation Database (gnomAD).
The amino acid residue of p.(Arg107Trp) is located in a
highly evolutionary conserved region by multiple alignments
of 100 vertebrates shown in UCSC Genome Browser with a
high GERP score of 5.91 for mammalian alignment. In silico
analysis including SIFT, Polyphen-2, and Mutation Taster
also predicted that the residue was located in highly con-
served region and p.(Arg107Trp) was predicted to be
damaging to the protein structure and function. Using the
3D modeling by STRUM, the p.(Arg107Trp) variant results
a delta-delta G value of 0.57. A positive delta-delta G value
implies the variant is responsible for COQ7 protein fold
stabilization.10
Sanger sequencing of the identified variants in parental
DNA was performed and showed that the variants were seg-
regated between the parents. Father is the carrier of frame-
shift variant and mother is the carrier of missense variant.
According to ACMG classification,11 the frameshift variant
falls into the tier of “Likely pathogenic.” It was predicted to
undergo nonsense mediated decay with the exon present in
the biologically-relevant transcript.12 The missense variant
falls into the tier of “Uncertain significance” with a Post_P
value 0.5 using the Bayesian classification framework.13
2.3 | Reverse transcription polymerase chain
reaction
RNA was extracted from patient's fibroblasts and semi-
quantitative reverse transcription polymerase chain reaction
was performed to amplify the COQ7 complementary DNA
(cDNA) consisting of the region with the two variants found.
Sanger sequencing of the cDNA revealed that only the allele
with the missense variant was expressed while cDNA with
the frameshift variant was not identified. This finding illus-
trated that the mRNA with the frameshift variant could be
eliminated by nonstop decay pathway which targets tran-
scripts that do not have an in-frame stop codon.14
2.4 | Respiratory chain enzymologies analysis
Measurement of the respiratory chain succinate: cytochrome
c oxidoreductase activity in skin fibroblasts revealed a sig-
nificant decrease of combined complex II + III (114 mU/
UCOX; reference: 325-649) while the isolated activity of
complex II and complex III were within the normal range.
Fibroblast CoQ10 quantification showed a reduced level to
0.29 nmol/UCOX (reference: 1.64-3.32). The result of these
analyses indicated that this patient has CoQ10 deficiency.
3 | DISCUSSION
3.1 | Third reported case of pathogenic
variant in COQ7
In this study, we reported the third case of COQ7 defect
associated with primary CoQ10 deficiency through WES.
This again demonstrated that WES is an important molecular
diagnostic test for mitochondrial disorders as a similar clini-
cal phenotype (such as multiple organ involvement) can be
resulted from mutations of different mitochondrial or nuclear
FIGURE 1 Magnetic resonance imaging brain images of the
index subject. A, T2W hyperintense cystic changes involving bilateral
corona radiata, basal ganglia and thalami, compatible with old lacunar
infarcts, cerebral atrophy with encephalomalacic changes in bilateral
frontal lobes. B, Doublet lactate peaks on magnetic resonance
spectroscopy
Abbreviation: MRI, magnetic resonance imaging
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genes.9 We have chosen skin biopsy as a less invasive inves-
tigation for complex activity and CoQ10 level because a pre-
vious study illustrated that analysis of fibroblasts was useful
to demonstrate a deficiency even though the muscle showed
false negative results.15 However, a normal CoQ10 level in
fibroblasts did not exclude CoQ10 deficiency in some
cases.16,17 Tissue specificity suggested that the choice of
appropriate tissues is important and study of different tissues
in case of a negative result is necessary to confirm CoQ10
deficiency.
3.2 | Comparison with previous cases of
COQ7 and COQ9 deficiency
Our subject presented with encephalo-myo-nephro-cardiopathy,
persistent lactic acidosis and basal ganglia lesions. The
clinical presentation of our patient was comparable to one
of reported classical phenotypes of CoQ10 deficiency as
encephalomyopathy with hypertrophic cardiomyopathy,
lactic acidosis and tubulopathy4 and this verified that
COQ7 deficiency could cause multiple organ involvement.
There were many similarities between our index subject
and that of the previously reported cases of COQ7 defi-
ciency. All three subjects had hearing impairment and
global developmental delay or intellectual disability, with
involvement of the peripheral nervous system. Despite the
similarities, there were also many notable differences
among the three cases. Our index subject had a fatally pro-
gressive multisystemic involvement with cardiac failure
and clinically significant tubulopathy. The MRI brain
showed typical features of a mitochondrial disorder which
were absent in the previously reported cases. What remains
to be better ascertained, is the response to CoQ10 supple-
ments. A comparison of the three patients is available in
Table 1.
Different types and positions of the COQ7 variants could
alter the function of COQ7 protein in different ways and affect
the presenting phenotypes of the patients. The second case
study demonstrated that the variant p.(Leu111Pro) showed a
milder reduction in CoQ10 level than the p.(Val141Glu) vari-
ant in the first case and so the phenotype of the second case is
milder.7 The p.(Val141Glu) variant next to p.Glu142 residue
is predicted to be part of the di-iron motif and was suggested
to impair iron binding for hydroxylation.18 The p.(Arg107Trp)
variant in the present study was located in another highly con-
served region but the biological significance of that region is
not well-studied. The 3D modeling by STRUM implies that
the p.(Arg107Trp) variant is responsible for COQ7 protein
fold stabilization.10 Further, mutations at the COQ7 Arg107
residue is predicted to affect the interaction with COQ9, dis-
rupting the CoQ10 biosynthesis.
19 A change from Arg to Trp
results in an increased size, increased in hydrophobicity and a
loss in charge, suggesting a loss of interactions with other mol-
ecules. Further in-vitro investigation on COQ7 structure and
function can provide more insights to the phenotype-genotype
relationship.
As COQ9 was suggested to interact with COQ7 physically
and functionally in CoQ10 biosynthesis,
20 the clinical pheno-
types were compared. Up till now, six patients from three fami-
lies were reported to have COQ9 deficiency.21–23 Both COQ7
and COQ9 deficiency may cause a multisystemic disorder with
encephalopathy, lactic acidosis and a variable combination of
cardiopathy and nephropathy. However, patients with biallelic
COQ9 mutations all had severely intractable symptoms caus-
ing neonatal or infantile death and a lack of response to CoQ10
supplementation, similar to our index patient. Intriguingly, the
other two patients with biallelic COQ7 mutations as mentioned
above had a much milder phenotype with variable response to
CoQ10. Understanding the precise role of COQ9 in CoQ10 bio-
synthesis would be necessary to explain the phenotypic differ-
ence between COQ7 and COQ9 deficiency.
3.3 | Role of CoQ10 supplements in
mitochondrial disorders
In contrast to the first case with the clinical progression
being stabilized by CoQ10 treatment, our patient had no
response to CoQ10 supplementation at a recommended dose
of 20 mg/kg/day.24 However, a higher dose of 30 mg/kg/day
could have been tried.25 CoQ10 deficiency is potentially
treatable by CoQ10 supplementation but the outcomes are
still variable. Different tissue involvements in different cases
may influence the responsiveness to CoQ10 treatments. In a
previous report, CoQ10 supplementation is effective in
patient with COQ2 defect manifested with neurological
signs, nephrotic syndrome or stroke-like episode involving
vascular structures.26 Besides, improvements including bet-
ter coordination, decrease in muscle weakness, better speech
articulation, etc. were reviewed.27 However, the responses
of central nervous system are poor for some patients such as
Leigh syndrome caused by PDSS2 defects and refractory
seizures resulting from COQ9 mutations.22,28 Other neuro-
logical symptoms including developmental delay were also
not improved.27 Possible contributing factors are poor bio-
availability of CoQ10 leading to poor penetration across the
blood-brain barrier and presence of irreversible brain dam-
age before CoQ10 treatment.
29 These can be the reasons for
poor CoQ10 responsiveness in our patient, owing to the early
progressive and severe neurological damages.
As demonstrated by this first report,6 2,4-dihydroxybensoic
acid (2,4DHB), a CoQ10 biosynthetic precursor with an addi-
tional hydroxyl group which is normally added by COQ7, was
able to rescue the CoQ10 deficiency in patient fibroblasts by
bypassing the need for COQ7 and this finding was supported
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by another in vivo study.30 On the other hand, the second case
report demonstrated that 2,4DHB, at the same time, can inhibit
native CoQ10 biosynthesis.
7 In Caenorhabditis elegans model,
overexpression of the CLD1 gene, encoding a phospholipase A,
restored CoQ10 wildtype levels, suggesting a recovery of
COQ7 function by structural remodeling.31 All these studies
highlighted nonlinearity of CoQ10 biosynthesis and opened up
alternative treatment strategies for CoQ10 deficiency.
In conclusion, the present study reported a severe case of
COQ7-associated primary CoQ10 deficiency with progressive
and fatal encephalo-myo-nephro-cardiopathy not responding to
CoQ10 treatment. Alternative treatment strategies should be
developed for a more effective management of this disorder.
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